Artelo Biosciences gets Nasdaq panel exception to cure listing deficiencies by March 30

ARTELO BIOSCIENCES, INC.

Panel granted exception to regain compliance with $2.5M stockholders' equity rule by March 30, 2026.
Company held 2025 annual meeting on Jan 30, curing annual meeting rule deficiency previously cited by Nasdaq.
Company previously received delist determination in Nov 2025; hearing stayed action.
Company intends to take all reasonable measures to regain compliance, but no assurance of success.
Failure to demonstrate compliance by March 30 could result in delisting from Nasdaq.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.